Page last updated: 2024-09-02

tamibarotene and Hematologic Malignancies

tamibarotene has been researched along with Hematologic Malignancies in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hara, S; Jimi, S; Mashima, K; Matsumoto, T; Suzumiya, J; Tamura, K	1

Other Studies

1 other study(ies) available for tamibarotene and Hematologic Malignancies

Article	Year
RARalpha is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells. International journal of oncology, 2007, Volume: 31, Issue:2 Topics: Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Genes, Tumor Suppressor; Hematologic Neoplasms; HL-60 Cells; Humans; K562 Cells; Phosphorylation; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoids; Tetrahydronaphthalenes; Transforming Growth Factor beta2	2007

Article

Year

RARalpha is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells.

International journal of oncology, 2007, Volume: 31, Issue:2

Topics: Apoptosis; Benzoates; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Genes, Tumor Suppressor; Hematologic Neoplasms; HL-60 Cells; Humans; K562 Cells; Phosphorylation; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoids; Tetrahydronaphthalenes; Transforming Growth Factor beta2

2007